NCT05129605
- Conditions
- ATM Gene Mutation, BRCA1 Mutation, BRCA2 Mutation, +35 more
- Locations
-
- Massachusetts General Hospital Boston, Massachusetts, United States
Clinical trial condition
BRCA2 Mutation
Explore clinical trials studying BRCA2 Mutation. Study availability and eligibility vary by location and protocol.
41 public trials
12 recruiting studies
BRCA2 Mutation trial results
NCT04095195
- Conditions
- BRCA1 Mutation, BRCA2 Mutation, Colonic Diseases, +34 more
- Locations
-
- Istituto Clinico Humanitas Rozzano, Milan, Italy
- Ospedale Pederzoli Peschiera del Garda, Verona, Italy
- San Raffele Vita Salute University Hospital Milan, Italy
- Chirurgia Generale e del Pancreas Verona, Italy
Not yet recruiting
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT07499999
- Conditions
- Adenocarcinoma, Ataxia Telangiectasia Mutated Gene Mutation, Atypical Lobular Hyperplasia, +16 more
- Locations
-
- Brigham and Women's Hospital Boston, Massachusetts, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States
Enrolling by invitation
Genetic Education in BRCA Families
NCT03544983
- Conditions
- Adnexal Diseases, BRCA1 Mutation, BRCA2 Mutation, +23 more
- Locations
-
- Georgetown University Medical Center/Lombardi Comprehensive Cancer Center Washington D.C., District of Columbia, United States
- George Washington University Washington D.C., District of Columbia, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- Geisinger Medical Center Danville, Pennsylvania, United States
Active, not recruiting
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
NCT06177171
- Conditions
- ATM Gene Mutation, BRCA Mutation, BRCA1 Mutation, +3 more
- Locations
-
- University of California, San Francisco San Francisco, California, United States
Active, not recruiting
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660
- Conditions
- Adnexal Diseases, BRCA1 Mutation, BRCA2 Mutation, +27 more
- Locations
-
- Chongqing Cancer Hospital Chongqing, Chongqing Municipality, China
- Fujian Cancer Hospital Fuzhou, Fujian, China
- Sun Yat-Sen University Cancer Center Guangzhou, Guangdong, China
- Anyang Cancer Hospital Anyang, Henan, China
Active, not recruiting
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
NCT05498272
- Conditions
- BRCA1 Mutation, BRCA2 Mutation, Genital Diseases, +12 more
- Locations
-
- University of California San Diego - Moores Cancer Center La Jolla, California, United States
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
- Columbia University Irving Medical Center New York, United States
- Memorial Sloan Kettering Cancer Center New York, United States
Active, not recruiting
BRCA1/2 Flu Vaccine
NCT04499534
- Conditions
- BRCA1 Mutation, BRCA2 Mutation
- Locations
-
- University of Pennsylvania Philadelphia, Pennsylvania, United States
Active, not recruiting
FaCT Trial (Facilitated Cascade Testing Trial)
NCT04613440
- Conditions
- BRCA1 Mutation, BRCA2 Mutation, Fanconi Anemia, Complementation Group D1
- Locations
-
- Weill Cornell Medicine New York, United States
- Duke University Durham, North Carolina, United States
- MD Anderson Cancer Center Houston, Texas, United States
Active, not recruiting
BRCA Founder OutReach (BFOR) Study
NCT03351803
- Conditions
- BRCA1 Mutation, BRCA2 Mutation
- Locations
-
- University of California, Los Angeles Los Angeles, California, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
- Memorial Sloan - Kettering Cancer Center New York, United States